Non Interventional Post Marketing Programme in Neuroendocrine Tumours
NCT00747786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2019-01-07
Summary
The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability in patients receiving their injection from a healthcare professional (HCP) ("Reference Group").
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2013-04-30
- Completion
- 2013-08-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization
NCT02552745 ·Status: COMPLETED
-
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
NCT05883176 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01004978 ·Status: COMPLETED ·Phase: PHASE3
-
SynOV1.1 Intratumoral Injection Study
NCT04612504 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma
NCT05981066 ·Status: RECRUITING ·Phase: NA
-
Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
NCT00807300 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
NCT01507168 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
NCT03812874 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT05987176 ·Status: TERMINATED ·Phase: PHASE2
-
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
NCT04946305 ·Status: COMPLETED
-
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
NCT07281664 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04487067 ·Status: COMPLETED ·Phase: PHASE3
-
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
NCT04224636 ·Status: RECRUITING ·Phase: PHASE2
-
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
NCT04563338 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
NCT02743065 ·Status: UNKNOWN
-
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT04732286 ·Status: TERMINATED ·Phase: PHASE3
-
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT01409499 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
NCT05761717 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
NCT00703365 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
NCT04338685 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
NCT01839630 ·Status: COMPLETED
-
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
NCT03941873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
NCT06463522 ·Status: RECRUITING ·Phase: PHASE1/PHASE2